SUNLENCA 464 mg, solution for injection 2 bottles of 1.5 ml + 2 needles
Active ingredients: Lenacapavir, Lenacapavir sodium
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection2 bottles of 1.5 ml + 2 needlessous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SUNLENCA 464 mg, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 2 flacon(s) en verre de 1,5 ml + 2 adaptateur(s) pour flacon + 2 seringue(s) + 2 aiguille(s)
- Marketing authorisation holder
- GILEAD SCIENCES IRELAND UC (IRLANDE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 20 Dec 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
65950064CIP73025806CIP133400930258064Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉNACAPAVIRsolution | 464 mg · 1,5 mL de solution | FT |
| LÉNACAPAVIR SODIQUEsolution | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.